• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4595296)   Today's Articles (822)   Subscriber (49331)
Number Citation Analysis
51
Li Y, Jiang H, Qian F, Cheng Y, Zhang Y, Lu J, Lou Y, Han B, Zhang W. 81P Is PD-1 inhibitor based treatment better than chemotherapy for metastatic NSCLC patients with PD-L1≥50% who develop EGFR-TKI resistance? A real-world investigation. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
52
Di J, Xiong Y, Li D, Li X, Wang W, Cheng Y, Li T. Primary pulmonary hyalinising clear cell carcinoma: Two cases and literature review. THE MALAYSIAN JOURNAL OF PATHOLOGY 2022;44:509-516. [PMID: 36591718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
53
Wang F, Gong XL, Geng HY, Cheng Y, Chen XN. [A case of asymptomatic immune checkpoint inhibitor associated myocarditis and myositis]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2022;50:1103-1105. [PMID: 36418279 DOI: 10.3760/cma.j.cn112148-20220811-00618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
54
Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Sun Y, Hu X, Jensen E, Schwarzenberger P, Paz-Ares L. 328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
55
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Kang W, Wang Q, Zhu J. LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]  Open
56
Wang J, Lv X, Wang S, Wu Y, Gao G, Wang J, Cheng Y, Cao F, Liu Q. Risk Factors of Treatment-Related Pneumonitis after Thoracic Radiotherapy/Chemoradiotherapy Combined with Anti-PD-1 mAb in Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
57
Zhang X, Wu YL, Chen Y, Zhang H, Wu G, Lu Y, Liang Z, Hu Y, Cheng Y, Wang J, Ying J, Liu W, Liang Z. 266P Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]  Open
58
Zhou C, Lu Y, Kim SW, Baisamut (Reungwetwattana) T, Zhou J, Zhang Y, He J, Yang J, Cheng Y, Lee SH, Chang J, Fang J, Liu Z, Bu L, Qian L, Xu T, Archer V, Hilton M, Zhou M, Zhang L. LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
59
Yang J, Zhou J, M. li, Zhang ZY, Cheng Y, Chu D, Pan H, Wang B, Chen G, Wang K, Jiang L, Hu Y, Shi J, Hui AM, Zhou Y, Wu Z, Sun J, Tan Y, Xiang X, Wu YL. 392P A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
60
Bukis K, Cheng Y, Armstrong M, Conte J, Coote K, Allaire N, Sivachenko A, Mense M, Cotton C, Valley H. 634 Generation of a cystic fibrosis transmembrane conductance regulator R1162X “TAG” model and comparison of readthrough to the naturally occurring R1162X “TGA”. J Cyst Fibros 2022. [PMCID: PMC9527874 DOI: 10.1016/s1569-1993(22)01324-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
61
Allaire N, Yoon J, Armstrong M, Valley H, Macadino C, Sivachenko A, Conte J, Tabak B, Bihler H, Cheng Y, Coote K, Cotton C, Mense M. 663 Modulation of cystic fibrosis transmembrane conductance regulator intron 22 alternative polyadenylation use may have therapeutic potential for the treatment of certain 3′ cystic fibrosis transmembrane conductance regulator premature termination codon variants. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01353-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
62
Zheng P, Li Y, Chi Q, Cheng Y, Jiang X, Chen D, Mu Y, Shen J. Structural characteristics and microbial function of biofilm in membrane-aerated biofilm reactor for the biodegradation of volatile pyridine. JOURNAL OF HAZARDOUS MATERIALS 2022;437:129370. [PMID: 35728312 DOI: 10.1016/j.jhazmat.2022.129370] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 05/26/2022] [Accepted: 06/09/2022] [Indexed: 06/15/2023]
63
Rodriguez-Abreu D, Wu YL, Boyer M, Garassino M, Mok T, Cheng Y, Hui R, Kowalski D, Robinson A, Brahmer J, Leal T, Lopes G, Cho B, Nogami N, Novello S, Peled N, de Castro G, Leiby M, Chirovsky D, Lin J, Pietanza M, Reck M. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
64
Cheng Y, Wu L, Huang D, Wang Q, Fan Y, Liu Z, Fan H, Yao W, Liu B, Yu G, Pan Y, Xu F, He Z, Dong X, Ma R, Min X, Ge X, Chen H, Liu Q, Hu Y, Liu Y, Song W, Yang C, Sun S. EP08.02-078 Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
65
Wang J, Cheng Y, Wu Y, Cao F, Liu Q, Gao G. 1262TiP Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
66
Smit E, Felip E, Uprety D, Nakagawa K, Paz-Ares L, Pacheco J, Li B, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Saxena K, Shiga R, Cheng Y, Yan Q, Feng W, Jänne P. 975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
67
John T, Ciuleanu TE, Cobo Dols M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Cheng Y, Felip E, Juan Vidal O, Alexandru A, Paz-Ares L, Lu S, Reck M, Hu N, Zhang X, Grootendorst D, Eccles L, Carbone D. 1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
68
Li B, Smit E, Goto Y, Nakagawa K, Goto K, Mazieres J, Uprety D, Bazhenova L, Saltos A, Felip E, Pacheco J, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Yan Q, Planchard D, Jänne P. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
69
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Wang Y, Li S, Yu C, Rivalland G. EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
70
Ding K, Liu Y, Song Y, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Yuan Y. 441TiP A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
71
Wang M, Yang JH, Mitchell P, Fang J, Nian W, Chiu C, Zhou J, Zhao Y, Su WC, Camidge D, Yang TY, Zhu V, Millward M, Fan Y, Cheng Y, Jiang L, Zheng L, Jänne P. 987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
72
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Chen C, Jin X, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S. EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
73
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Wang Y, Ghassemifar S, Li S, Rivalland G. 1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
74
Novello S, Kowalski D, Luft A, Gumus M, Vicente Baz D, Mazieres J, Rodriguez Cid J, Tafreshi A, Cheng Y, Lee K, Golf A, Sugawara S, Robinson A, Halmos B, Jensen E, Schwarzenberger P, Pietanza M, Paz-Ares L. 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
75
Li J, Pu X, Zhang B, Zhang J, Mok T, Nakagawa K, Rosell R, Cheng Y, Zhou X, Migliorino M, Niho S, Lee K, Corral J, Pluzanski A, Li J, Linke R, Pan F, Tang Y, Tan W, Wu L. EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
PrevPage 3 of 54 123455354Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA